Dienogest PCD Pharma Franchise Company
Cafoli Lifecare offers a Dienogest range of 2 tablet formulations, manufactured in WHO-GMP certified facilities. Distributors serving gynaecology prescribers can secure district-wise monopoly franchise rights for this endometriosis-specific progestin with full promotional support.
What is Dienogest?
Dienogest is a fourth-generation progestin with selective progestogenic activity on the endometrium. Taken continuously it suppresses the growth of endometriotic tissue and relieves associated pelvic pain, making it a first-line medical therapy for endometriosis. Reference: PubChem - Dienogest.
Available Forms
The Cafoli Dienogest portfolio is offered as oral Tablets (typically 2mg), including combinations with estradiol. Contact us for current pack presentations and combinations.
Therapeutic Applications
Dienogest is prescribed for the management of endometriosis and associated pelvic pain, and in combination for contraception and menstrual disorders. Prescribers are chiefly gynaecologists and reproductive-medicine specialists.
Why Dienogest is a High-Potential Molecule for Distributors
Endometriosis affects a large share of women of reproductive age and is increasingly diagnosed and treated, and dienogest is the go-to oral therapy prescribed for long, continuous courses. As a specialist-driven, extended-duration women-health molecule with limited PCD competition, it offers distributors dependable repeat volume and healthy margins.
Why Choose Cafoli Lifecare
Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.
References
- PubChem: Dienogest
- PubMed: dienogest in endometriosis
- MedlinePlus: Endometriosis
Our formulations of Dienogest find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: